Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in The Netherlands, has successfully increased its outstanding EUR 300 million 4.00% bond due 2015 by EUR 200 million. The increase, triggered by interest of investors, has been placed to institutional investors across Europe.

The proceeds will be used for general corporate purposes. The terms of the notes are in line with those of the existing 4.00% bond due 2015 issued on 10 November 2005. The terms are laid down in the EUR 2 billion Debt Issuance Program of Royal DSM N.V., the final terms and the supplements thereto, which are available on the Investor Relations website.

The issue price of the EUR 200 million notes was 89.646%. Based on this price the yield is 5.808%. The bond is listed on Euronext Amsterdam.

This release does not constitute an offer or an invitation to subscribe for or purchase any securities. The notes are being offered only by means of a prospectus.

DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com